TRX.L

Tissue Regenix Group Plc
Tissue Regenix Group - Confirmation of results
21st August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1644B
Tissue Regenix Group PLC
21 August 2024
 

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

 

Confirmation of results

Investor presentation

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms that the Group's interim results for the six months ended 30 June will be announced on Tuesday 10 September 2024.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Tuesday 10 September 2024. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

 

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

 

 

For more information:

 

Tissue Regenix Group plc

www.tissueregenix.com

Daniel Lee, Chief Executive Officer

David Cocke, Chief Financial Officer

via Walbrook PR



Cavendish Capital Markets Limited (Nominated Adviser and Broker)


Emily Watts/Geoff Nash/ Edward Whiley - Corporate Finance


Nigel Birks/Harriet Ward - ECM


 


Walbrook PR (Financial PR and IR)

Tel: +44 (0)20 7933 8780

Charlotte Edgar / Alice Woodings

TissueRegenix@walbrookpr.com



 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASEUFWSELSESA]]>
TwitterFacebookLinkedIn